113 related articles for article (PubMed ID: 11910269)
1. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.
Begré S; von Bardeleben U; Ladewig D; Jaquet-Rochat S; Cosendai-Savary L; Golay KP; Kosel M; Baumann P; Eap CB
J Clin Psychopharmacol; 2002 Apr; 22(2):211-5. PubMed ID: 11910269
[TBL] [Abstract][Full Text] [Related]
2. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
Uehlinger C; Crettol S; Chassot P; Brocard M; Koeb L; Brawand-Amey M; Eap CB
J Clin Psychopharmacol; 2007 Jun; 27(3):273-8. PubMed ID: 17502774
[TBL] [Abstract][Full Text] [Related]
3. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Eap CB; Broly F; Mino A; Hämmig R; Déglon JJ; Uehlinger C; Meili D; Chevalley AF; Bertschy G; Zullino D; Kosel M; Preisig M; Baumann P
J Clin Psychopharmacol; 2001 Apr; 21(2):229-34. PubMed ID: 11270921
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
Brøsen K; Hansen JG; Nielsen KK; Sindrup SH; Gram LF
Eur J Clin Pharmacol; 1993; 44(4):349-55. PubMed ID: 8513845
[TBL] [Abstract][Full Text] [Related]
7. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
[TBL] [Abstract][Full Text] [Related]
8. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
10. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.
Eap CB; Bondolfi G; Zullino D; Savary-Cosendai L; Powell-Golay K; Kosel M; Baumann P
J Clin Psychopharmacol; 2001 Jun; 21(3):330-4. PubMed ID: 11386497
[TBL] [Abstract][Full Text] [Related]
12. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
13. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
14. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Schneider F; Stamler D; Bradbury MJ; Loupe PS; Gordon MF; Rabinovich-Guilatt L
Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
[TBL] [Abstract][Full Text] [Related]
15. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
16. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
17. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.
Coller JK; Joergensen C; Foster DJ; James H; Gillis D; Christrup L; Somogyi AA
Int J Clin Pharmacol Ther; 2007 Jul; 45(7):410-7. PubMed ID: 17725248
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; White JM; Bochner F
Br J Clin Pharmacol; 2004 Jun; 57(6):742-55. PubMed ID: 15151520
[TBL] [Abstract][Full Text] [Related]
19. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.
Glue P; Winter H; Garbe K; Jakobi H; Lyudin A; Lenagh-Glue Z; Hung CT
J Clin Pharmacol; 2015 Jun; 55(6):680-7. PubMed ID: 25651476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
